185315-48-4

Usage

Uses

Used in Pharmaceutical Industry:
(4-Bromo-2-chlorophenyl)methanol is used as a key intermediate in the synthesis of various pharmaceuticals and agrochemicals. Its presence in the molecular structure of these compounds contributes to their therapeutic effects and helps in the treatment of various diseases and conditions.
Used in Fragrance and Flavor Industry:
(4-Bromo-2-chlorophenyl)methanol is used as a building block in the production of fragrances and flavors. Its unique chemical structure imparts distinct scents and tastes to the final products, making it a valuable component in the creation of various consumer goods.
Used as a Chiral Auxiliary in Organic Synthesis:
(4-Bromo-2-chlorophenyl)methanol is used as a chiral auxiliary in the preparation of chiral drugs. Its ability to induce chirality in the synthesized compounds aids in the development of enantiomerically pure drugs, which are essential for ensuring the desired therapeutic effects and minimizing potential side effects.
Used in the Development of New Molecules and Materials:
(4-Bromo-2-chlorophenyl)methanol serves as a versatile building block in organic chemistry, with potential applications in the development of new molecules and materials. Its unique structure and properties make it a valuable component in the synthesis of innovative compounds with diverse applications.
Used in Antimicrobial and Antifungal Applications:
(4-Bromo-2-chlorophenyl)methanol has been studied for its potential antimicrobial and antifungal properties. Its ability to inhibit the growth of various microorganisms makes it a valuable compound for the pharmaceutical and agricultural industries, where it can be used to develop new antimicrobial agents and protect crops from fungal infections.

Upstream product

• 59748-90-2 4-Bromo-2-chloro-benzoic Acid 
• 185312-82-7 4-bromo-2-chlorobenzoic acid methyl ester 
• 25118-59-6 4-bromo-3-chlorobenzoic acid 
• 89794-02-5 4-bromo-2-chlorotoluene 
• 158435-41-7 4-bromo-2-chlorobenzaldehyde 

Downstream Products

• 158435-41-7 4-bromo-2-chlorobenzaldehyde 
• 219764-24-6 2-chloro-4-vinylbenzyl alcohol 
• 219762-46-6 4-bromo-2-chloro-1-((methanesulfonyloxy)-methyl)benzene 
• 279252-19-6 4-bromo-1-((tert-butyldiphenylsilyloxy)methyl)-2-chlorobenzene 
• 219764-17-7 2-Chloro-4-(thiophene-2-yl)benzyl alcohol 
• 89720-77-4 4-bromo-1-bromomethyl-2-chlorobenzene 
• 1417736-19-6 {4-[4-amino-7-(morpholin-4-ylmethyl)pyrrolo[2,1-f][1,2,4]triazin-5-yl]-2-chlorophenyl}methanol 
• 1213929-66-8 C₉H₉BrClNO₂ 
• 1432502-36-7 C₁₄H₁₇BrClNO₄ 
• 1432502-37-8 C₂₀H₂₃BrClNO₇ 
• 1432502-38-9 C₂₀H₂₅BrClNO₆ 
• 1432502-39-0 C₁₆H₁₉BrClNO₃ 
• 1432502-40-3 C₁₁H₁₁BrClNO 
• 1432502-41-4 C₁₆H₁₉BrClNO₂ 

Relevant academic research and scientific papers

Triazole derivative as well as preparation method and application thereof

The invention relates to a triazole derivative as well as a preparation method and application thereof, which belong to the technical field of organic synthetic drugs. The structure of the triazole derivative is shown as a formula I. In the formula I, R1 and R2 are H, Cl, Br,-CF3,-CH(CH3)2 or -OCH3, and R1 and R2 are not H at the same time. R3 is -CH2 or -COCH2; X and Y are N or C, X and Y are not C at the same time, and X and Y are not N at the same time. The triazole derivative disclosed by the invention has a certain inhibition effect on germs of various crop diseases. Small toxic andside effects on plants are achieved. The preparation method of the triazole derivative is simple.

HISTONE METHYLTRANSFERASE EZH2 INHIBITOR, PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF

The invention relates to a histone methyltransferase EZH2 inhibitor, a preparation method and pharmaceutical use thereof. In particular, the invention relates to a compound represented by the general formula (I), a preparation method thereof, a pharmaceut

Stilbene Boronic Acids Form a Covalent Bond with Human Transthyretin and Inhibit Its Aggregation

Transthyretin (TTR) is a homotetrameric protein. Its dissociation into monomers leads to the formation of fibrils that underlie human amyloidogenic diseases. The binding of small molecules to the thyroxin-binding sites in TTR stabilizes the homotetramer and attenuates TTR amyloidosis. Herein, we report on boronic acid-substituted stilbenes that limit TTR amyloidosis in vitro. Assays of affinity for TTR and inhibition of its tendency to form fibrils were coupled with X-ray crystallographic analysis of nine TTR·ligand complexes. The ensuing structure-function data led to a symmetrical diboronic acid that forms a boronic ester reversibly with serine 117. This diboronic acid inhibits fibril formation by both wild-type TTR and a common disease-related variant, V30M TTR, as effectively as does tafamidis, a small-molecule drug used to treat TTR-related amyloidosis in the clinic. These findings establish a new modality for covalent inhibition of fibril formation and illuminate a path for future optimization.

IMMUNE ADJUSTMENT COMPOUND, USE THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING SAME

The present invention provides a compound represented by formula I, wherein R is a halogen element or a C1-C6 alkyl group. The compound has S1 P1 receptor agonist activity and selective specificity and has obviously-shortened half-life in-vivo, and therefore the compound is a high-quality second-generation S1P1 receptor agonist. The present invention also provides a use of the compound in preparing medicine for treating diseases or symptoms mediated by an S1P1 receptor, a pharmaceutical composition comprising the compound, and uses of the compound and the pharmaceutical composition in treating diseases or symptoms mediated by the S1 P1 receptor.

An optimized synthesis of the potent and selective Pak1 inhibitor FRAX-1036

FRAX-1036 is a p21-activated kinase I inhibitor of significant interest to cancer biologists yet no commercial providers or detailed procedures are available. In this Letter, we chronicle the optimized synthesis of FRAX-1036, one of the most specific Pak1

Modulators of methyl modifying enzymes, compositions and uses thereof

Agents for modulating methyl modifying enzymes, compositions and uses thereof are provided herein.

NEPRILYSIN INHIBITORS

In one aspect, the invention relates to compounds having the formula I: where R1-R6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising these compounds; methods of using these compounds; and processes and intermediates for preparing these compounds.

NEPRILYSIN INHIBITORS

In one aspect, the invention relates to compounds having the formula (I): where R1-R6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising these compounds; methods of using these compounds; and processes and intermediates for preparing these compounds.

FATTY ACID SYNTHASE INHIBITORS

This invention relates to novel spirocyclic piperidines according to Formula (I) which are inhibitors of fatty acid synthase (FAS), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.

PAR2 RECEPTOR ANTAGONISTS

Compounds of formula (I) or pharmaceutically acceptable salts, solvates or hydrates thereof wherein P, Q, X, Y, R1, R2, R3, R10, R11, and R12 are as defined in the claims, and the use those compounds in medicine.